William P. Parker, MD, discusses the initial use of MRI and emergence of multiparametric MRI (mpMRI) in the field of prostate cancer care. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.